<DOC>
	<DOCNO>NCT00810095</DOCNO>
	<brief_summary>The primary study objective ass feasibility use MindFrame System safely effectively restore blood flow thrombotic neurovascular occlusion patient experience ischemic stroke .</brief_summary>
	<brief_title>Percutaneous Recanalization Ischemic Stroke Management ( PRIISM ) : A Feasibility Clinical Study</brief_title>
	<detailed_description>The objective PRIISM ass feasibility use MindFrame System safely effectively restore blood flow thrombotic neurovascular occlusion patient acute ischemic stroke . Safety assess device-related serious event rate compare similar therapy . The event include limited symptomatic hemorrhage , vessel dissection , embolization overall morbidity mortality . Target vessel include basilar , internal carotid middle cerebral ( M1 M2 segment ) artery .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>1 . NIHSS 6 30 within 6 hour symptom onset 2 . Prestroke Modified Rankin Score â‰¤ 2 3 . Large Vessel Occlusion 4 . Patient/patient guardian willing comply protocol requirement return treatment center require clinical evaluation . 5 . Patients must meet least one follow criterion : Eligible Intravenous rtPA Eligible Intraarterial rtPA IA rtPA initiate within 6 hour symptom onset Patient present within 6 hour symptom onset 1 . Pregnancy 2 . Glucose &lt; 50mg/dL 3 . Known hemorrhagic diathesis , coagulation factor deficiency , oral anticoagulant therapy INR &gt; 3.0 4 . Patient receive heparin within 48 hour PTT great 2 time lab normal . 5 . Patient baseline platelet &lt; 30,000 6 . Evidence rapidly improve neurological sign stroke time enrollment 7 . Coma 8 . Preexisting neurological psychiatric disease could confound study result 9 . Known severe allergy contrast medium nitinol 10 . Patient severe sustain hypertension 11 . CT/MRI scan reveals significant mass effect midline shift 12 . Patient 's angiogram show arterial stenosis &gt; 50 % proximal embolus . 13 . Patient 's anticipated life expectancy le 3 month 14 . Participation another clinical investigation could confound evaluation study device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Cerebral Infarction</keyword>
	<keyword>Stroke</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Penumbra</keyword>
	<keyword>Functional Outcome</keyword>
	<keyword>Aphasia</keyword>
	<keyword>Hemiplegia</keyword>
	<keyword>Left side weakness</keyword>
	<keyword>Right Sided weakness</keyword>
</DOC>